TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Trump Says Anthropic No Longer Seen as National Security Threat 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).
The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.
This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.
The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.
This article was generated with AI assistance and reviewed by an editor.
